VERIPURE
LIVE

Serial Number

97628473

Owner

Provectus Pharmatech, Inc.

Attorney

Daan G. Erikson

Filing Date

Oct 12, 2022

Add to watchlist:

No watchlists yet
View on USPTO

VERIPURE Trademark

Serial Number: 97628473

VERIPURE is a trademark filed by Provectus Pharmatech, Inc. on October 12, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Provectus Pharmatech, Inc.

800 S. Gay St., Suite 1610
Knoxville, TN 37929

Entity Type: 03

Trademark Details

Filing Date

October 12, 2022

Registration Date

Not Registered

Published for Opposition

March 4, 2025

Goods & Services

Diagnostic reagents for in virology, microbiology and ophthalmology

Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of tumors; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of solid tumors, namely, melanoma, breast cancer, basal cell carcinoma, prostate cancer, and small cell and non-small cell lung cancer, squamous cell carcinoma and primary and metastatic liver cancers; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of pediatric solid tumors, namely, Ewing sarcoma, neuroblastoma, osteosarcoma, neuroepithelioma, and rhabdomyosarcoma; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia, namely, acute B-cell lymphoblastic leukemia, T-cell lymphoblastic leukemia, acute myeloid leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of psoriasis; Preparations for pharmaceutical skin care; Diagnostic preparations for medical use, namely, for use in virology, microbiology, ophthalmology; Diagnostic mediums for use in virology, microbiology, ophthalmology; Pharmaceutical preparations and substances for use as vaccine adjuvants, immune system stimulators or suppressors, and immune system modulators

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 16, 2026 EXRA
SOU EXTENSION 2 GRANTED
Apr 16, 2026 EX2G
SOU EXTENSION 2 FILED
Apr 16, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 16, 2026 EEXT
ASSIGNED TO EXAMINER
Jan 24, 2026 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 21, 2025 EXRA
SOU EXTENSION 1 GRANTED
Oct 21, 2025 EX1G
SOU EXTENSION 1 FILED
Oct 21, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 21, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 29, 2025 NOAM
PUBLISHED FOR OPPOSITION
Mar 4, 2025 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2025 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 10, 2025 CNSA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 12, 2024 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Feb 14, 2024 RCSC
CORRESPONDENCE E-MAILED
Aug 17, 2023 GRML
SUSPENSION LETTER WRITTEN
Aug 17, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 17, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 17, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 27, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 17, 2022 NWOS
NEW APPLICATION ENTERED
Oct 15, 2022 NWAP